Latest Content

Novo Nordisk has launched the Medicare GLP-1 Bridge, making Wegovy available to eligible Medicare beneficiaries for $50 a month through the end of 2027, giving millions of older adults with obesity a structured pathway to the FDA-approved weight management drug.

AlzeCure Pharma has licensed its NeuroRestore platform and lead CNS candidate ACD856 to QuantumCell ApS, following positive Phase Ib safety and pharmacokinetic data.

Troutman Pepper Locke senior associate Ryan Last explains how thin margins on certain product will impact the effectiveness of tariffs.

In today's Pharmaceutical Executive Daily, FDA selects seven companies for its new PreCheck Pilot Program, Kirsten Whipple examines how the concept of healthspan is emerging from academic obscurity into a powerful consumer driver reshaping pharma's role in aging, and Pharmaceutical Executive speaks with Jeff Talbot of Roseman University of Health Sciences on how Las Vegas is positioning itself as an emerging life sciences hub beyond its casino-driven reputation.

Ryan Last, senior associate at Troutman Pepper Locke, details the key steps that pharma companies must make before the July 31st deadline hits.

A U.S. House committee has launched national security investigations into Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb over their clinical trial operations in China, seeking answers by July 17 on data protection, military hospital ties, and trial sites in Xinjiang.

FDA selected seven companies to participate in its new PreCheck Pilot Program, offering earlier regulatory engagement and expedited facility review to incentivize domestic drug manufacturing.

In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, Krista Pinto of Eversana argues that fully staffed pharma field teams are still missing revenue targets because the traditional deployment model itself needs to evolve, and EMA's CHMP issues a positive opinion recommending approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia across all lines of therapy in the European Union.

Zymeworks and Ipsen each announced acquisitions this week, with Zymeworks paying roughly $929 million for Theravance Biopharma to gain commercial COPD royalties and tax assets, and Ipsen committing up to $1.75 billion for Kartos Therapeutics to add navtemadlin.

The decision was made based on the results of the BRUIN CLL-313 clinical study.

Healthspan is merging from obscure academic jargon as a potent consumer driver, reshaping how people think about aging and redefining pharma’s role in that process.

New data from ADA 2026 reveal that assumptions around age, weight, and gestational history are leaving too many T1D patients misclassified — and the clinical consequences are preventable.

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic triple-negative breast cancer — as both a monotherapy and in combination with Keytruda — marking the first new backbone therapy option for this aggressive disease in more than two decades, Novartis announces a $105 million collaborative agreement with Antares Therapeutics to jointly discover and develop first-in-class precision medicines in oncology and other serious diseases, with potential milestones totaling $1.8 billion, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on the real-world benefits and persistent challenges of operating as a fully domestic manufacturer in an era of tariffs and supply chain pressure.